Annovis Bio, Inc. (ANVS) Stock Price & Analysis
Annovis Bio, Inc. (ANVS) rose 0.72% to USD 1.39 as of September 8, 2026 at 09:34 UTC, according to Nexqual real-time market data.
ANVS last closed at USD 1.39; the session ranged USD 1.38–1.44 on volume of 1,532,583 shares. Market capitalization is —, with a 52-week range of USD 1.32–5.5 (NYQ). Source: Nexqual, September 8, 2026 at 09:34 UTC.
Key Statistics (as of September 8, 2026 at 09:34 UTC)
| Price | USD 1.39 |
|---|---|
| Change | ▲ 0.72% (up) |
| Previous Close | USD 1.39 |
| Open | USD 1.39 |
| Day Range | USD 1.38 – 1.44 |
| 52-Week Range | USD 1.32 – 5.5 |
| Volume | 1,532,583 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (ANVS)
Nexqual's technical model rates ANVS "SELL" based on 3 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 09:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.3 (oversold) |
| vs SMA50 | Below (USD 1.78) |
| MACD | -0.07 (negative) |
From Annovis Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe that we are the only company developing a drug for AD and PD that inhibits more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity.
Partnerships
- In collaboration with the Alzheimer's Disease Cooperative Study ("ADCS"), we also conducted a trial in 16 early AD 5 Table of Contents patients (the "ADCS Trial").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AVXL | Anavex Life Sciences Corp. | USD 2.86 | ▼ 1.04% |
| INMB | INmune Bio Inc. | USD 2.44 | ▲ 3.83% |
| FLNA | Filana Therapeutics, Inc. | USD 0.82 | ▼ 4.64% |
| ACIU | AC Immune SA | USD 2.86 | ▲ 0.7% |
| LGVN | Longeveron Inc. | USD 6.81 | ▲ 0.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:34 UTC. This page is informational and not investment advice.